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ABSTRACT
Background    Adenoid cystic carcinoma (ACC) is a rel-
atively rare malignant neoplasm that occurs in salivary 
glands and various other organs. Recent studies have re-
vealed that a significant proportion of ACCs harbor gene 
alterations involving MYB or MYBL1 (mostly fusions 
with NFIB) in a mutually-exclusive manner. However, its 
clinical significance remains to be well-established.
Methods    We investigated clinicopathological and mo-
lecular features of 36 ACCs with special emphasis on the 
significance of MYBL1 alterations. Reverse-transcription 
polymerase-chain reaction (RT-PCR) and fluorescence 
in-situ hybridization (FISH) were performed to detect 
MYB/MYBL1–NFIB fusions and MYBL1 alterations, 
respectively. Immunohistochemistry was performed to 
evaluate MYB expression in the tumors. The results 
were correlated with clinicopathological profiles of the 
patients.
Results    RT-PCR revealed MYB–NFIB and MYBL1–
NFIB fusions in 10 (27.8%) and 7 (19.4%) ACCs, respec-
tively, in a mutually-exclusive manner. FISH for MYBL1 
rearrangements was successfully performed in 11 cases, 
and the results were concordant with those of RT-PCR. 
Immunohistochemically, strong MYB expression was 
observed in 23 (63.9%) tumors, none of which showed 
MYBL1 alterations. Clinicopathologically, a trend of a 
better disease-specific survival was noted in patients 
with MYBL1 alterations than in those with MYB–NFIB 
fusions and/or strong MYB expression; however, the 
difference was not significant. Interestingly, we found 
tumors with MYBL1 alterations significantly frequent-
ly occurred in the mandibular regions (P = 0.012). 
Moreover, literature review revealed a similar tendency 
in a previous study.
Conclusion    Our results suggest that there are some 
biological or etiological differences between ACCs with 
MYB and MYBL1 alterations. Moreover, the frequent 
occurrence of MYBL1-associated ACC in the mandibu-
lar regions suggests that MYB immunohistochemistry is 
less useful in diagnosing ACCs arising in these regions. 
Further studies are warranted to verify our findings.
Key words    adenoid cystic carcinoma; fluorescence 
in-situ hybridization; mandibular neoplasms; onco-
gene fusion; prognosis
Adenoid cystic carcinoma (ACC) is a relatively rare 
malignant neoplasm that occurs in various organs, 
including the major and minor salivary glands, nasal 
cavity, bronchial trees, and breast. ACC is characterized 
by a slow but relentless progression, showing an infil-
trative growth along the peripheral nerves and frequent 
distant metastases. Histologically, this tumor comprises 
epithelial and myoepithelial neoplastic cells showing 
diverse growth patterns, which are roughly subclassified 
into tubular/cribriform and solid types based on the 
dominant pattern. Due to the aggressive nature of the 
tumor, long-term prognosis in patients with ACC is poor, 
with the 10-year survival rate of 50%–70%.1 Currently, 
radical surgical resection with or without postoperative 
irradiation is the standard treatment for ACC; however, 
local recurrences are common with no effective che-
motherapeutic regimens known. Accordingly, further 
understanding of the molecular basis of ACC that can 
lead to the development of newer effective therapies is 
urgently required.
 Recently, a recurrent fusion of MYB and NFIB 
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transcription factor genes resulting from a translocation 
t(6;9) was discovered in ACC, and it was found to be as-
sociated with the overexpression of the fusion transcript 
containing the 5’ end of MYB.2 This MYB–NFIB fusion 
was later confirmed to be present in approximately 50% 
of ACCs, but not in non-ACC salivary gland tumors, 
which indicates that it is a specific and common driver 
of ACC tumorigenesis.3–6 Moreover, the overexpression 
of full-length or the 5’ end of MYB was observed in 
65%–80% of ACCs, including in those without MYB–
NFIB fusion, which suggests the presence of additional 
mechanisms for MYB overexpression in ACC. Indeed, 
Drier et al. have recently demonstrated that chromosom-
al rearrangements that reposition super-enhancers in 
NFIB or other gene loci to the vicinity of MYB result in 
the formation of a positive feedback loop that sustains 
MYB expression and suggested that these rearrange-
ments are the unifying features of ACCs overexpressing 
MYB with or without MYB–NFIB fusion.7
 Meanwhile, several studies have revealed that 
MYBL1—another member of the MYB gene family—
is also involved in ACC tumorigenesis. In fact, in 2015, 
two research groups independently reported that alter-
ations of this gene—mostly the formation of a MYBL1–
NFIB fusion—were noted in a small subset of ACCs and 
were associated with the overexpression of the 5’ end of 
MYBL1.8, 9 In addition, the genetic alterations involving 
MYB and MYBL1 were found to occur in a mutually ex-
clusive manner, which further supports that they are cru-
cial events that occur early in the ACC tumorigenesis. 
Moreover, although previous studies observed another 
subset of ACCs that apparently did not possess structural 
aberrations in both MYB and MYBL1 loci, Togashi et 
al. have recently suggested that nearly all ACCs actually 
harbor chromosomal rearrangements involving either 
of these two genes.10 Using multiple methods including 
fluorescence in-situ hybridization (FISH) with conven-
tional probe sets for MYB and MYBL1 split as well as 
a wide-range MYB probe set covering a much broader 
region (approximately 20 Mb) around MYB, they found 
that 97 of the 100 ACCs harbored rearrangements in 
either MYB or MYBL1 locus, and reported that 10 of 
them had atypical FISH patterns that were undetectable 
by ordinary FISH methods.
 As described above, recent studies have rapidly un-
covered molecular aberrations in ACC. However, their 
clinicopathological significance remains to be fully elu-
cidated. Although some studies reported that cases with 
MYB rearrangements detected by conventional FISH 
showed a trend toward shorter disease-free survival,5, 11 
the results were not statistically significant. Moreover, 
there are few studies investigating the correlation be-
tween MYBL1 rearrangements and patient outcome. In 
addition, although MYB and MYBL1 rearrangements 
were detected in ACCs of various organs throughout the 
body, the association between these rearrangements and 
specific body sites remain to be fully characterized. In 
the present study, we investigated the clinicopathological 
and molecular features of 36 cases of ACCs, with an 
emphasis on the significance of the MYBL1 rearrange-
ment.
MATERIALS AND METHODS
Case selection
The present study was approved by the Institutional 
Review Board of Tottori University, Faculty of Medicine 
(1610A121) and Tottori Prefectural Central Hospital 
(2017-15). We examined 36 cases of ACC diagnosed 
at the Tottori University Hospital or Tottori Prefectural 
Central Hospital. Cases in which formalin-fixed paraffin-
embedded (FFPE) specimens were available were 
included in the study. In all cases, the histological slides 
were reviewed by a board-certified pathologist of the 
Japanese Society of Pathology (S.K.) and the diagnosis 
was confirmed. Clinicopathological data of the patients 
were obtained from the data system of each facility. As 
for alcohol consumption status, the patients were classi-
fied into non/occasional drinkers or daily drinkers based 
on the patients’ self-report. The histology of ACC was 
graded into two categories: grade 1 or 2 (the solid com-
ponent was < 50%) and grade 3 (the solid component 
was ≥ 50%).10 Tumor extent was classified as localized 
(which is confined to the primary organ at diagnosis) 
or advanced (which directly invades the neighboring 
organs and/or metastasizes to regional lymph nodes or 
distant organs at diagnosis).
Reverse-transcription polymerase chain reaction 
(RT-PCR) for MYB–NFIB and MYBL1–NFIB fusions
To detect MYB–NFIB and MYBL1–NFIB fusions, RT-
PCR was performed using the following procedure: 
total RNA was extracted from each archival tissue 
using the PureLink FFPE RNA Isolation Kit (Thermo 
Fisher Scientific, Waltham, MA) and was converted 
into cDNA using the ReverTra Ace qPCR RT Master 
Mix with gDNA Remover (Toyobo, Osaka, Japan). PCR 
was performed using the TaKaRa Ex Taq Hot Start 
Version (Takara Bio, Kusatsu, Shiga, Japan), where the 
program consisted of an initial denaturation at 94°C 
for 4 min, followed by 40 cycles of denaturation (94°C, 
30 s), annealing (57°C, 30 s), and extension (72°C, 1 
min). The primer sequences are shown in Table 1. The 
exon numbers of MYB, MYBL1, and NFIB were defined 
according to the GenBank accession numbers U22376.1, 
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NM_001080416.3, and NM_001190738.1, respectively.12 
A 98-bp partial cDNA of β-actin was amplified as an in-
ternal control. The PCR products were electrophoresed 
on 2.0% agarose gels, stained with ethidium bromide, 
and visualized under UV illumination. The results were 
interpreted based on the product size. In some cases, 
Sanger sequencing was also performed for confirming 
that the fusion products were obtained as expected.
Immunohistochemistry
Immunohistochemical staining for MYB was performed 
on an automatic immunostainer (Autostainer Link 48, 
Dako, Glostrup, Denmark) using an anti-MYB rabbit 
monoclonal antibody (clone EP769Y, 1:200 dilution, 
Abcam, Cambridge, UK). Antigen retrieval was per-
formed by incubating the slides at 97°C for 20 min in 
citrate buffer (pH 6.0). The staining results was recorded 
as strong when ≥ 5% of myoepithelial cells in the tumor 
showed a distinct nuclear immunoreactivity, and as 
weak/negative when no or only weak immunoreactivity 
was observed throughout the tumor specimen. Because a 
weak immunoreactivity was observed in a subset of var-
ious non-ACC tumors,5 we considered that only a strong 
MYB immunoreactivity was significant. Moreover, 
as MYB immunoreactivity in ACC is known to be 
confined to myoepithelial cells,5 we did not evaluate 
immunoreactivity in luminal epithelial cells in tumors.
Fluorescence in-situ hybridization (FISH) for 
MYBL1 rearrangements
FISH analysis for detecting MYBL1 rearrangements 
was performed using bacterial artificial chromosome 
clone-derived probes covering the 3’ region (RP11-
346I3) and the 5’ region (RP11-110J18) of the MYBL1 
locus, where the probes were labeled with biotin and 
digoxigenin, respectively. The procedure was conducted 
as previously described.13, 14 Briefly, after sections were 
deparaffinized, heat-treated, and digested with pepsin, 
denaturation was performed by placing the sections in 
70% formamide/2X SSC solution. Then, hybridization 
was conducted by incubating the sections with the 
above probes at 37°C for approximately 48 h. After 
the post-hybridization washing, the biotin-labeled and 
digoxigenin-labeled probes were detected using avidin-
FITC (green) and anti-digoxigenin-rhodamine (red), 
respectively. The results were interpreted as positive 
(MYBL1 rearranged) when > 10% of cells that were 
observed exhibited at least one break-apart signal or a 
separation between green and red signals of more than 
two signal widths.15
Statistical analysis
According to the results of the above analysis, 31 of 
the 36 cases were classified as either MYBL1 or MYB 
genetic group (see Results for detail), and then clini-
copathological factors were compared between these 
groups. Fisher’s exact test, chi-square test, and Wilcoxon 
rank sum test were used, as appropriate. Difference in 
the disease-specific survivals between the two groups 
was investigated using the Kaplan–Meier method and 
the log-rank test. In addition, using similar methods, 
we also investigated the significance of the “length” of 
MYB/MYBL1–NFIB fusion transcripts among MYB/
MYBL1–NFIB-positive cases (see Results for detail). All 
statistical analyses were performed using SPSS version 
24 (IBM Corp., Armonk, NY). The results were consid-
ered statistically significant at P < 0.05.
RESULTS
Clinicopathological characteristics
The subjects included 9 men and 27 women of a median 
age at the time of diagnosis of 60.5 years (age range: 32–
86 years). Tumors occurred in the major salivary glands in 
16 cases (parotid = 7, sublingual = 5 and submandibular 
Table 1. RT-PCR primers used in the present study
Primers Direction Nucleotide sequence (5ʹ—> 3ʹ)
MYB Exon 8 Forward ACCGAGAATGAGCTAAAAGGACA
Exon 9 Forward ACCTCTTAGAATTTGCAGAAACAC
Exon 10 Forward AGAGACCAGACTGTGAAAACTCA
Exon 11 Forward ACACTTGGAAAGGAACCAAGCTA
Exon 12 Forward AATGGACCACCCTTACTGAAGA
Exon 13 Forward ACACTTGGAAAGGAACCAAGCTA
Exon 14 Forward ACAGTACCTAAAAACAGGTCCC
MYBL1 Exon 8 Forward GTCAGCTGAGAATGAAGTTAGAAGA
Exon 14 Forward AGAAGAATCAGGCACTCAACTG
NFIB Exon 9 Reverse ACACTTGGAAAGGAACCAAGCTA
RT-PCR, reverse-transcription polymerase chain reaction.
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Table 2. Results of immunohistochemistry and molecular genetic analysis of 36 cases of adenoid cystic carcinoma
Case No. Age Gender Location
IHC RT-PCR* FISH†
Genetic group‡
MYB Fusion Fusion pattern Exon–Exon MYBL1 split
ACC1 35 F Nasal cavity Strong − − Negative MYB
ACC2 48 F Parotid gland Strong MYB–NFIB Exon 12–Exon 9 n.d. MYB
ACC3 82 F Ear canal Strong − − Negative MYB
ACC4 61 F Sublingual gland None MYBL1–NFIB Exon 8–Exon 8CExon 8–Exon 9 n.d. MYBL1
ACC5 32 F Paranasal cavity Strong MYB–NFIB Exon 14–Exon 8CExon 14–Exon 9 n.d. MYB
ACC6 49 F Nasal cavity Strong MYB–NFIB Exon 14–Exon 8C n.d. MYB
ACC7 66 M Sublingual gland Weak MYBL1–NFIB Exon 8–Exon 8CExon 8–Exon 9 Positive MYBL1
ACC8 48 M Parotid Strong MYB–NFIB Exon 9–Exon 8CExon 9–Exon 9 n.d. MYB
ACC9 37 F Nasal cavity Strong − − Negative MYB
ACC10 62 F Paranasal cavity None MYBL1–NFIB Exon 14–Exon 8CExon 14–Exon 9 n.d. MYBL1
ACC11 69 F Sublingual gland None MYBL1–NFIB Exon 8–Exon 8C n.d. MYBL1
ACC12 50 M Sublingual gland Weak MYBL1–NFIB Exon 8–Exon 8CExon 8–Exon 9 n.d. MYBL1
ACC13 63 F Trachea Strong MYB–NFIB Exon 10–Exon 9 n.d. MYB
ACC14 54 F Paranasal cavity Strong − − failed MYB
ACC15 81 F Submandibular gland Strong − − failed MYB
ACC16 53 F Nasal cavity Strong MYB–NFIB Exon 12–Exon 9 n.d. MYB
ACC17 39 F Oropharynx Weak − − failed unknown
ACC18 84 M Trachea Weak − − failed unknown
ACC19 79 F Sublingual gland None MYBL1–NFIB Exon 8–Exon 9 n.d. MYBL1
ACC20 45 M Submandibular gland None − − failed unknown
ACC21 57 F Submandibular gland Weak MYB–NFIB Exon 12–Exon 9 n.d. MYB
ACC22 55 F Parotid gland None − − failed unknown
ACC23 77 F Submandibular gland Strong − − Negative MYB
ACC24 62 F Orbital Strong − − failed MYB
ACC25 71 F Parotid gland Strong − − Negative MYB
ACC26 73 F Nasal cavity Strong − − failed MYB
ACC27 63 M Floor of mouth Strong − − Negative MYB
ACC28 60 F Palate Strong MYB–NFIB Exon 14–Exon 9 n.d. MYB
ACC29 73 M Nasal cavity Weak − − Negative unknown
ACC30 33 M Nasal cavity Strong − − Negative MYB
ACC31 66 M Lung Strong MYB–NFIB Exon 14–Exon 8CExon 14–Exon 9 n.d. MYB
ACC32 69 F Parotid gland Strong MYB–NFIB Exon 14–Exon 8CExon 14–Exon 9 n.d. MYB
ACC33 86 F Parotid gland Strong − − Negative MYB
ACC34 34 F Palate Weak MYBL1–NFIB Exon 8–Exon 8CExon 8–Exon 9 n.d. MYBL1
ACC35 59 F Parotid gland Strong − − Negative MYB
ACC36 74 F Trachea Strong − − n.d. MYB
*“−” indicates that no fusions were detected. †Failed indicates that the FISH result was uninterpretable (no signals observed, etc.). 
‡Genetic group was determined according to the results of IHC, RT-PCR and FISH (see Results for detail). Unknown indicates that the 
results were insufficient to subclassify the case. ACC, adenoid cystic carcinoma; F, female; FISH, fluorescence in-situ hybridization; IHC, 
Immunohistochemistry; M, male; n.d., not done; RT-PCR, reverse-transcription polymerase chain reaction.
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= 4); nasal/paranasal cavity in 10; bronchial trees in 4; 
palate in 2, and the fl oor of mouth, ear, oropharynx and 
orbital cavity in 1 each. Of these, 25 patients had local-
ized disease, and the remaining 11 had advanced disease 
at the time of diagnosis. Surgical removal of the tumor 
was performed in 26 cases, with 11 of them receiving 
postoperative radiation therapy. Eight patients received 
radiation therapy alone, and the other 2 received only 
palliative therapy. Histologically, 30 (83.3%) tumors 
were classifi ed as grade 1/2 and 6 (16.6%) as grade 3. 
Seven patients died during the follow-up period, and six 
of them died of ACC. The median follow-up period for 
patients who were alive at the last follow-up was 90.0 
months (range: 13–233 months).
RT-PCR
Internal control cDNA (β-actin) was successfully am-
plifi ed in all 36 cases. Among them, fusion transcripts 
of MYB–NFIB and MYBL1–NFIB were detected in 10 
(27.8%) and 7 (19.4%) cases, respectively, and they were 
mutually exclusive. The fusion patterns differed from 
one case to another in both MYB–NFIB- and MYBL1–
NFIB-positive groups (Table 2, Fig. 1). In nine cases, 
two amplifi cation products with different lengths were 
detected, where the longer products corresponded to 
alternatively spliced transcript variants that contained 
NFIB exon 8C. In the remaining 19 cases, no fusion 
transcripts were detected in this assay.
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Fig. 1. Breakpoints of MYB and MYBL1 within the MYB–NFIB and MYBL1–NFIB fusion transcripts detected by reverse-
transcription polymerase chain reaction. Yellow arrows indicate the positions of the primers used in the present study (not to scale). Blue 
vertical bars indicate the positions of the breakpoints, with the number of cases being indicated above them.
Immunohistochemistry
Immunohistochemically, a strong expression of MYB 
was observed in 23 (63.9%) of 36 cases, whereas no or 
only weak expression was noted in the remaining 13 
cases (Table 2, Fig. 2). Of the 10 cases in which MYB–
NFIB fusion transcripts were detected by RT-PCR, a 
strong expression of MYB was observed in 9 (90%) 
cases. On the other hand, among the seven cases in 
which MYBL1–NFIB fusion transcripts were detected 
by RT-PCR, none showed strong MYB expression. In 
many MYB-positive cases, the staining was often lim-
ited to the periphery of the tumors. It was judged from 
the previous reports that this occurred because formalin 
fi xation was delayed and the half-life of MYB protein 
was short.6 However, in these peripheral areas, strong 
MYB expression was observed at least 40% of the tumor 
myoepithelial cells in all MYB-positive ACCs.
FISH analysis 
FISH analysis for MYBL1 rearrangements was per-
formed in 18 of the 19 cases in which no fusions were 
detected in RT-PCR (in the remaining 1 case, no spec-
imen was available for FISH analysis). In addition, a 
selected MYBL1–NFIB-positive case determined by RT-
PCR (ACC7) was included in the analysis as a positive 
control. Of these 19 cases, the results were interpretable 
in 11 cases, and MYBL1 rearrangements were detected 
only in the MYBL1–NFIB-positive case (Table 2; Figs. 
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Table 3. Clinicopathological comparison between MYBL1 and MYB genetic groups (Analysis of 31 cases)
Total
Genetic group P value†MYBL1 (%) MYB (%)
Number of cases 31 7 (22.6) 24 (77.4)
Age 59.5 ± 14.7 64.6 ± 15.6 58.0 ±14.7 0.228
Gender Male 6 1 (16.7) 5 (83.3) 1.000
Female 25 6 (24.0) 19 (76.0)
Size (cm) 2.8 ± 1.0 2.9 ± 0.6 2.8 ± 1.1 0.448
Smoking No 21 5 (23.8) 16 (76.2) 0.599
Yes 10 2 (20.0) 8 (80.0)
Drinking Occasional/non 24 5 (20.8) 19 (79.2) 1.000
Daily 4 1 (25.0) 3 (75.0)
Primary tumor site (1) Major salivary glands 14 5 (35.7) 9 (64.3) 0.197
Minor salivary glands 11 2 (18.2) 9 (81.8)
Others‡ 6 0 (0.0) 6 (100.0)
Primary tumor site (2) Mandibular regions§ 9 5 (55.6) 4 (44.4) 0.012*
Others 22 2 (9.1) 20 (90.9)
Histological grade Grade 1/2 27 6 (22.2) 21 (77.8) 0.662
Grade 3 4 1 (25.0) 3 (75.0)
Tumor extent Advanced 9 2 (22.2) 7 (77.8) 1.000
Localized 22 5 (22.7) 17 (77.3)
*Statistically signifi cant. †Fisher’s exact test, chi-square test, and Wilcoxon rank sum test. ‡Include external auditory canal, pharynx, and 
orbital. §The mandibular regions contain the following parts: Submandibular gland, Sublingual gland, and Floor of mouth.
Fig. 2. Representative images for histology (A and D, hematoxylin-eosin), MYB immunohistochemistry (B and E), and MYBL1 break-apart 
FISH (C and F) of adenoid cystic carcinomas. A–C: ACC3, in which neither MYB–NFIB nor MYBL1–NFIB were detected by RT-PCR, 
showing a typical cribriform histology (A), a strong immunoreactivity for MYB (B), and no evidence of MYBL1 rearrangement (white 
arrows) (C). D–F: ACC7, in which MYBL1–NFIB fusion was detected by RT-PCR, showing a typical cribriform histology (D), only a 
weak immunoreactivity for MYB (E), and MYBL1 rearrangement (yellow arrows; red, 5’ MYBL1; green, 3’ MYBL1) (F). Bars = 10 µm. 
ACC, adenoid cystic carcinoma; FISH, fl uorescence in-situ hybridization; RT-PCR, reverse-transcription polymerase chain reaction.
(D) (E) (F)
(A) (B) (C)
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ations and clinicopathological factors, we noticed that 
tumors with MYBL1 alterations predominantly occurred 
in the mandibular regions (i.e., on the floor of the 
mouth, sublingual glands, and submandibular glands). 
Therefore, we decided to investigate this point in greater 
detail and found that tumors with MYBL1 alterations 
occurred signifi cantly frequently in these regions as than 
in those with MYB–NFIB fusions and/or strong MYB 
expression (P = 0.012) (Table 3). Moreover, review of 
the literature from this perspective revealed a similar 
tendency in a previous study,9 with the difference being 
statistically significant. However, in the other studies, 
such a tendency was not observed.8, 10, 14, 16
Impact of the length of MYB/MYBL1–NFIB fusion 
transcripts on clinicopathological factors
Previous studies revealed that the gene expression pro-
fi les in ACCs with MYB/MYBL1 rearrangements were 
different between those with “long fusions” containing 
the C-terminal negative regulatory domains of MYB/
MYBL1 and those with “short fusions” that lacked such 
domains.9 Moreover, it has also been demonstrated in 
a reporter gene assay that MYB/MYBL1–NFIB fusion 
constructs that lack the negative regulatory domains dis-
played signifi cantly higher transcriptional activity than 
those containing the domains.8 Therefore, we addition-
ally investigated clinicopathological differences between 
ACCs with “long fusions” containing breakpoints after 
exon 12 of MYB/MYBL1 (n = 9) and those with “short 
fusions” containing breakpoints before exon 12 (n = 
8). Consequently, however, we observed no significant 
differences between cases with long and short fusions in 
any of the clinicopathological factors, including progno-
sis (data not shown).
DISCUSSION
In the present study, we confirmed several previous 
observations regarding molecular aberrations in ACCs, 
as follows: i) a substantial subset of ACCs harbor MYB–
NFIB or MYBL1–NFIB fusions, ii) gene alterations 
involving MYB and MYBL1 occur in a mutually exclu-
sive manner, and iii) overexpression of MYB protein is 
well-correlated with MYB alterations and not observed 
in tumors with MYBL1 alterations. These findings 
clearly indicate that MYB and MYBL1 alterations are the 
crucial events that occur early in the ACC tumorigene-
sis. Furthermore, recent studies demonstrated that chro-
mosomal rearrangements involving MYB in ACC create 
a positive feedback loop that sustains MYB expression,7
which suggests that the overexpression of MYB (and 
probably also MYBL1) is indispensable for the growth 
and maintenance of ACC cells. Therefore, the inhibition 
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Fig. 3. Kaplan–Meier curves depicting disease-specifi c survival 
for patients with adenoid cystic carcinoma stratified by genetic 
group (MYBL1, n = 7; MYB, n = 24). Log-rank test, P = 0.174.
2C and F). The other 10 cases showed no evidence of 
MYBL1 rearrangement.
Correlation between gene alterations and clinico-
pathological factors
From the recent observation that almost all ACCs harbor 
chromosomal rearrangements involving either MYB
or MYBL1,10 we hypothesized that most tumors in the 
present study also actually harbored genetic alterations 
involving either of these 2 genes. Moreover, as previous 
studies revealed that the overexpression of MYB and 
MYBL1 in ACCs was mutually exclusive and highly 
correlated with genetic alterations involving MYB and 
MYBL1, respectively,9, 10 we considered that tumors 
showing strong MYB expression in immunohistochem-
istry can be regarded as those that actually harbor genet-
ic alterations involving MYB. Accordingly, we compared 
the clinicopathological factors between cases with 
MYBL1 alterations (MYBL1 group, n = 7) and those 
with MYB–NFIB fusions and/or strong MYB expression 
(MYB group, n = 24). As a result, however, we found no 
significant differences between these two groups with 
regard to patient age, gender, smoking and drinking 
status, tumor size, primary tumor site, histological 
grade, and tumor extent at the time of diagnosis (Table 
3). Disease-specific survival was also not significantly 
different between these 2 groups, although there was a 
trend toward a more favorable prognosis in patients with 
MYBL1 alterations (P = 0.174, log-rank test) (Fig. 3).
Detailed analysis of the association between gene 
alterations and tumor primary site
During analysis of the correlation between gene alter-
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of MYB/MYBL1 or their downstream signaling path-
ways is a promising novel treatment of ACC, and such 
molecular targeted therapies may contribute to the im-
provement of the survival and quality of life of patients 
with unresectable/metastatic ACCs.
 It is notable that MYBL1 alterations were significant-
ly frequently noted in ACCs that arose from the mandib-
ular regions in our cohort. To the best of our knowledge, 
this is the first study in which the relationship of genetic 
alterations and specific body sites was suggested in 
ACCs. Inspired by this observation, we conducted a lit-
erature review from this perspective and found a similar 
result in one past study,9 although such a difference was 
not observed in other studies.8, 10, 14, 16 The reason for this 
discrepancy is unclear and may be attributable to chance 
or sampling bias. However, the correlation of specific 
gene fusions and body sites has been suggested in sever-
al other tumors. For example, the EML4-ALK fusion is 
known to be found in approximately 4% of lung adeno-
carcinomas, but is generally not found in tumors of other 
organs,17 although it has been reported in a few colorec-
tal and breast cancers and renal cell carcinomas.18, 19 
Similarly, in inflammatory myofibroblastic tumors, most 
cases are shown to harbor gene fusions involving ALK 
or ROS1, where the EML4-ALK is predominantly found in 
tumors arising in the lungs.20, 21 Therefore, similar to the 
relationship between EML4-ALK fusion and lungs, there 
may be unknown mechanisms or etiological factors that 
result in the formation of MYBL1-rearranged tumors in 
the mandibular regions. Further studies are hence war-
ranted to assess this point in greater detail.
 The potential relationship of MYBL1 alterations and 
the mandibular regions has some clinical significance. 
In a previous study,22 an immunohistochemical panel 
including MYB was reported to be useful in distin-
guishing ACCs from pleomorphic adenomas and other 
salivary gland neoplasms. However, because ACCs 
with MYBL1 alterations never exhibit a strong MYB 
expression, such an immunohistochemical panel may be 
less useful in assessing tumors arising in the mandibular 
regions. Accordingly, it is advisable for pathologists and 
cytopathologists to be aware of this potential pitfall, 
since the diagnosis of salivary gland tumors can some-
times be challenging, especially in fine-needle aspiration 
cytology or small biopsy specimens.
 It is difficult to explain why ACCs with MYBL1 
alterations are frequent in the mandibular regions. This 
is because that mechanisms causing the formation of 
specific gene fusion remain largely unknown, although 
chromosome translocations in general are known to 
be caused by inappropriate religation of two DNA 
double-strand breaks generated by endogenous or 
exogenous sources.23 Possible explanations for the asso-
ciation between MYBL1 alterations and the mandibular 
regions include that the break in the MYBL1 locus may 
be resulted from exposure to some kinds of exogenous 
agents that are taken orally. However, we did not find 
any correlations between MYBL1 alterations and pa-
tients’ smoking history and alcohol consumption status. 
Another explanation is that MYBL1 may be actively 
expressed in specific cells in the mandibular regions, 
and the gene locus is loosely packed and thus is suscep-
tible to physical DNA damage and subsequent erroneous 
repair.
 Despite no statistically significant difference noted, 
we found a trend toward a more favorable prognosis in 
patients in the MYBL1 group as compared with those 
in the MYB group. Notably, no patients in the MYBL1 
group died of ACC during the follow-up period (range: 
29–124 months; median: 71 months), whereas 6 (28.6%) 
of the 21 patients in the MYB group died of ACC at 
2–86 months after diagnosis. These results are in line 
with those of several previous studies. For example, 
Mitani et al. have noted a significantly shorter survival 
in patients with MYB alterations as compared to that 
in patients with MYBL1 alterations.9 Moreover, prior 
to the discovery of MYBL1 alterations in ACCs, the 
same study group have reported that patients high MYB 
expression showed a significantly poorer prognosis 
compared to those with low MYB expression (presum-
ably the latter group consisted mainly of patients with 
high MYBL1 expression).4 Similarly, West et al. have 
reported that ACCs with MYB translocation showed a 
trend (not significant) toward higher local relapse rates 
as compared with those with no abnormalities detected 
in FISH.5 Although data may be insufficient to draw a 
definitive conclusion, these results suggest that ACCs 
with MYB alterations behave more aggressively than 
those with MYBL1 alterations, and that there are some 
differences in the biological effects between MYB and 
MYBL1 altered in ACC cells.
 There are few studies regarding to the difference 
in treatment response between ACCs with MYB and 
MYBL1 alterations. This is mainly because that the mo-
lecular aberrations in ACC are only recently identified, 
and clinical research is yet limited due to the rarity and 
slow growth kinetics of the tumors.24 However, since 
previous studies have shown consistently low response 
rates to chemotherapy for metastatic ACCs,24 it is 
unlikely that tumors with MYB and MYBL1 alterations 
respond differently to cytotoxic chemotherapies. On the 
other hand, recent and ongoing clinical trials evaluating 
efficacy of molecularly targeted therapies and cancer 
immunotherapies may reveal different response rates 
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among different genetic groups of ACCs. For example, 
in a recent report of clinical study of axitinib (a receptor 
tyrosine kinase inhibitor) for patients with incurable 
ACC, Ho et al. noted that a trend (not significant) toward 
superior progression-free survival was observed with 
the MYB/NFIB rearrangement.25 Future research may 
delineate the impact of the type of genetic aberrations 
on medical therapies for patients with incurable ACC.
 In this study, there were 13 ACCs that showed a 
strong MYB expression in immunohistochemistry 
despite no MYB–NFIB fusions detected by RT-PCR. 
In these cases, molecular aberrations different from the 
MYB–NFIB fusion formation are considered to have 
resulted in MYB overexpression. For example, previous 
studies have demonstrated that i): fusions between 
MYB and genes other than NFIB (such as PDCD1LG2, 
EFR3A, TGFBR3 and RAD51B),4, 7 ii): fusions between 
MYB and intergenic sequences downstream of the 3’ 
untranslated region of NFIB,4, 10 and iii): fusions between 
the 5’ end of NFIB and genes around the MYB locus (such 
as NKAIN2 and AIG1) 4, 9 were associated with MYB 
overexpression in ACCs. As the unifying features of 
these various genetic alterations, Drier et al. have recent-
ly advocated a model that chromosomal rearrangements 
that relocate super-enhancers within the loci of NFIB 
or other genes to the vicinity of MYB results in the 
formation of a positive feedback loop that sustains MYB 
expression.7 It is highly likely that such rearrangements 
have also occurred in the 13 cases of our cohort.
 There are several limitations to the present study. 
First, the size of the study group is relatively small, as 
only 36 patients were included in the study. Second, 
gene alterations involving MYB and MYBL1 were not 
completely investigated. Although MYB/MYBL1–
NFIB fusion is the dominant pattern of gene alterations 
involving MYB/MYBL1 in ACCs, since other alterations 
noted in some ACCs are diverse, we were unable to 
detect such alterations in the present study using FFPE 
specimens. Moreover, we performed MYBL1 break-
apart FISH to identify additional tumors with MYBL1 
alterations, but the results were interpretable only in 11 
of the 19 tumors. Accordingly, the importance of appro-
priate fixation and storage of FFPE tissues for molecular 
analysis was reaffirmed through the present study.
 In conclusion, we conducted a clinicopathological 
and molecular analysis using 36 cases of ACC and noted 
a potential relationship between MYBL1 alterations and 
the mandibular regions. On survival analysis, we ob-
served a trend toward a longer disease-specific survival 
in patients with MYBL1 alterations as compared with 
that in patients with MYB–NFIB fusions and/or strong 
MYB expression. The shortcomings of the study includ-
ed the small sample size, which may have resulted in the 
low statistical power to detect some of the differences 
between tumors with MYB and MYBL1 alterations. 
Further research with larger cohorts is thus required to 
verify the results in the present study.
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